Page 1606 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 87 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma 1431.e1

REFERENCES 24. Sahota SS, Forconi F, Ottensmeier CH, et al: Typical Waldenström
macroglobulinemia is derived from a B-cell arrested after cessation of
1. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of somatic mutation but prior to isotype switch events. Blood 100:1505,
Waldenström’s macroglobulinemia: consensus panel recommendations 2002.
from the Second International Workshop on Waldenström’s Macro- 25. Ackroyd S, O’Connor SJM, Owen RG: Rarity of IgH translocations
globulinemia. Semin Oncol 30:110, 2003. in Waldenström macroglobulinemia. Cancer Genet Cytogenet 163:77,
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American 2005.
classification of lymphoid neoplasms: a proposal from the International 26. Avet-Loiseau H, Garand R, Lode L, et al: 14q32 translocations discrimi-
Lymphoma Study Group. Blood 84:1361, 1994. nate IgM multiple myeloma from Waldenström’s macroglobulinemia.
3. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization Semin Oncol 30:153, 2003.
classification of neoplastic diseases of the hematopoietic and lymphoid 27. Braggio E, Keats JJ, Leleu X, et al: High-resolution genomic analysis
tissues: report of the Clinical Advisory Committee meeting, Airlie in Waldenström’s macroglobulinemia identifies disease-specific and
House, Virginia, November, 1997. Ann Oncol 10:1419, 1999. common abnormalities with marginal zone lymphomas. Clin Lym-
4. Groves FD, Travis LB, Devesa SS, et al: Waldenström’s macroglobu- phoma Myeloma 9:39, 2009.
linemia: incidence patterns in the United States, 1988–1994. Cancer 28. Schop RF, Kuehl WM, Van Wier SA, et al: Waldenström macro-
82:1078, 1998. globulinemia neoplastic cells lack immunoglobulin heavy chain
5. Herrinton LJ, Weiss NS: Incidence of Waldenström’s macroglobulin- locus translocations but have frequent 6q deletions. Blood 100:2996,
emia. Blood 82:3148, 1993. 2002.
6. Hanzis C, Ojha RP, Hunter Z, et al: Associated malignancies in patients 29. Hunter ZR, Xu L, Yang G, et al: The genomic landscape of Walden-
with Waldenström’s macroglobulinemia and their kin. Clin Lymphoma strom macroglobulinemia is characterized by highly recurring MYD88
Myeloma Leuk 11:88, 2011. and WHIM-like CXCR4 mutations, and small somatic deletions
7. Bjornsson OG, Arnason A, Gudmunosson S, et al: Macroglobulinae- associated with B-cell lymphomagenesis. Blood 123:1637, 2014.
mia in an Icelandic family. Acta Med Scand 203:283, 1978. 30. Nguyen-Khac F, Lambert J, Chapiro E, et al: Chromosomal aberrations
8. Renier G, Ifrah N, Chevailler A, et al: Four brothers with Waldenström’s and their prognostic value in a series of 174 untreated patients with
macroglobulinemia. Cancer 64:1554, 1989. Waldenström’s macroglobulinemia. Haematologica 98:649, 2013.
9. Treon SP, Hunter ZR, Aggarwal A, et al: Characterization of familial 31. Braggio E, Keats JJ, Leleu X, et al: Identification of copy number
Waldenström’s macroglobulinemia. Ann Oncol 17:488, 2006. abnormalities and inactivating mutations in two negative regulators of
10. Ogmundsdottir HM, Sveinsdottir S, Sigfusson A, et al: Enhanced B nuclear factor-κB signaling pathways in Waldenström’s macroglobulin-
cell survival in familial macroglobulinaemia is associated with increased emia. Cancer Res 69:3579, 2009.
expression of Bcl-2. Clin Exp Immunol 117:252, 1999. 32. Leleu X, Eeckhoute J, Jia X, et al: Targeting NF-κB in Waldenström
11. Santini GF, Crovatto M, Modolo ML, et al: Waldenström macroglobu- macroglobulinemia. Blood 111:5068, 2008.
linemia: a role of HCV infection? Blood 82:2932, 1993. 33. Treon SP, Hunter ZR, Matous J, et al: Multicenter clinical trial of
12. Silvestri F, Barillari G, Fanin R, et al: Risk of hepatitis C virus infection, bortezomib in relapsed/refractory Waldenström’s macroglobulinemia:
Waldenström’s macroglobulinemia, and monoclonal gammopathies. results of WMCTG Trial 03-248. Clin Cancer Res 13:3320, 2007.
Blood 88:1125, 1996. 34. Treon SP, Tripsas CK, Meid K, et al: Carfilzomib, rituximab and
13. Leleu X, O’Connor K, Ho A, et al: Hepatitis C viral infection is dexamethasone (CaRD) is active and offers a neuropathy-sparing
not associated with Waldenström’s macroglobulinemia. Am J Hematol approach for proteasome-inhibitor based therapy in Waldenström’s
82:83, 2007. macroglobulinemia. Blood 124:503, 2014.
14. Swerdlow SH, Campo E, Harris NL, et al: WHO classification of 35. Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in
tumours of haematopoietic and lymphoid tissues, ed 4, Lyon, France, Waldenström’s macroglobulinemia. N Engl J Med 367:826, 2012.
2008, IARC Press. 36. Xu L, Hunter Z, Yang G, et al: MYD88 L265P in Waldenström
15. Smith BR, Robert NJ, Ault KA: In Waldenström’s macroglobulinemia macroglobulinemia, immunoglobulin M monoclonal gammopathy,
the quantity of detectable circulating monoclonal B lymphocytes cor- and other B-cell lymphoproliferative disorders using conventional and
relates with clinical course. Blood 61:911, 1983. quantitative allele-specific polymerase chain reaction. Blood 121:2051,
16. Treon SP: How I treat Waldenström’s macroglobulinemia. Blood 114: 2013.
2375, 2009. 37. Varettoni M, Arcaini L, Zibellini S, et al: Prevalence and clinical
17. Preud’homme JL, Seligmann M: Immunoglobulins on the surface significance of the MYD88 L265P somatic mutation in Waldenström
of lymphoid cells in Waldenström’s macroglobulinemia. J Clin Invest macroglobulinemia, and related lymphoid neoplasms. Blood 121:2522,
51:701, 1972. 2013.
18. San Miguel JF, Vidriales MB, Ocio E, et al: Immunophenotypic analysis 38. Jiménez C, Sebastián E, Del Carmen Chillón M, et al: MYD88 L265P
of Waldenström’s macroglobulinemia. Semin Oncol 30:187, 2003. is a marker highly characteristic of, but not restricted to, Waldenström’s
19. Hunter ZR, Branagan AR, Manning R, et al: CD5, CD10, and CD23 macroglobulinemia. Leukemia 27:1722, 2013.
expression in Waldenström’s macroglobulinemia. Clin Lymphoma 39. Poulain S, Roumier C, Decambron A, et al: MYD88 L265P mutation
5:246, 2005. in Waldenström’s macroglobulinemia. Blood 121:s4504, 2013.
20. Paiva B, Montes MC, García-Sanz R, et al: Multiparameter flow 40. Ansell SM, Hodge LS, Secreto FJ, et al: Activation of TAK1 by MYD88
cytometry for the identification of the Waldenström’s clone in IgM L265P drives malignant B-cell growth in non-Hodgkin lymphoma.
MGUS and Waldenström’s macroglobulinemia: new criteria for Blood Cancer J 4:e183, 2014.
differential diagnosis and risk stratification. Leukemia 28:166, 41. Ngo VN, Young RM, Schmitz R, et al: Oncogenically active MYD88
2013. mutations in human lymphoma. Nature 470:115, 2011.
21. Wagner SD, Martinelli V, Luzzatto L: Similar patterns of V κ gene 42. Landgren O, Staudt L: MYD88 L265P somatic mutation in IgM
usage but different degrees of somatic mutation in hairy cell leukemia, MGUS. N Engl J Med 367:2255, 2012.
prolymphocytic leukemia, Waldenström’s macroglobulinemia, and 43. Yang G, Zhou Y, Liu X, et al: A mutation in MYD88 (L265P) sup-
myeloma. Blood 83:3647, 1994. ports the survival of lymphoplasmacytic cells by activation of Bruton
22. Aoki H, Takishita M, Kosaka M, et al: Frequent somatic mutations in tyrosine kinase in Waldenström macroglobulinemia. Blood 122:1222,
D and/or JH segments of Ig gene in Waldenström’s macroglobulinemia 2013.
and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but 44. Watters T, Kenny EF, O’Neill LAJ: Structure, function and regulation
not in common CLL. Blood 85:1913, 1995. of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85:411,
23. Shiokawa S, Suehiro Y, Uike N, et al: Sequence and expression analyses 2007.
of mu and delta transcripts in patients with Waldenström’s macroglobu- 45. Cohen L, Henzel WJ, Baeuerie PA: IKAP is a scaffold protein of the
linemia. Am J Hematol 68:139, 2001. IκB kinase complex. Nature 395:292, 1998.